

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan (MHRA-100523-PIP01-22-M01) and to the deferral

MHRA-100523-PIP01-22-M02

### **Scope of the Application**

#### **Active Substance(s)**

gadopiclenol

#### **Condition(s)**

Detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes.

#### **Pharmaceutical Form(s)**

Solution for injection

#### **Route(s) of Administration**

INTRAVENOUS

#### **Name / Corporate name of the PIP applicant**

Guerbet

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Guerbet submitted to the licensing authority on 28/03/2023 16:28 BST an application for a Modification

The procedure started on 24/07/2023 11:14 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100523-PIP01-22-M02

Of 09/08/2023 11:56 BST

On the adopted decision for gadopiclesol (MHRA-100523-PIP01-22-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for gadopiclesol, Solution for injection , INTRAVENOUS USE .

This decision is addressed to Guerbet, BP 57400, Roissy CdG , FRANCE, 95943

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Not applicable

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Detection and visualisation of areas with disruption of the blood brain barrier and/or abnormal vascularity for diagnostic purposes

#### 2.2 Indication(s) targeted by the PIP:

MRI in brain (intracranial), spine and associated tissues to detect and visualise areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

### 2.4 Pharmaceutical Form(s):

Solution for injection

### 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an additional volume for the solution for injection to avoid risk of overdose. (Same as Study 1 in MHRA-100524-PIP01-22-M01 and its subsequent modifications)
Non-Clinical Studies	2	Study 2 Dose-range finding toxicity study in rats to determine the toxicity of gadopiclesol in the neonatal and juvenile (pre-post weaning) rats in order to determine appropriate dose levels for the definitive juvenile rat study. (Study the same as Study 2 in MHRA-100524-PIP01-22-M01 and its subsequent modifications) Study 3 Definitive juvenile toxicity study to determine the toxicity of gadopiclesol in the neonatal and juvenile (pre-post weaning) rats. (Same as Study 3 in MHRA-100524-PIP01-22-M01 and its subsequent modifications)
Clinical Studies	2	Study 4 (GDX-44-007) Non-comparative pharmacokinetics, efficacy and safety study in children from 2 years to less than 18 years of age presenting central nervous system (CNS) lesions (intracranial, spine and associated tissues), who are scheduled to undergo routine contrast-enhanced MRI of CNS or body. (Same as Study 4 in MHRA-100524-PIP01-22-M01 and its subsequent modifications) Study 5 (GDX-44-015) Non-comparative

		pharmacokinetic, efficacy and safety study in children from birth to less than 2 years of age scheduled to undergo routine contrast-enhanced MRI of CNS or body. (Same as Study 5 in MHRA-100524-PIP01-22-M01 and its subsequent modifications)
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	0	Not applicable.
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	No
<b>Date of completion of the paediatric investigation plan:</b>	31/12/2024
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes